Evidence map›Paper›PMID 39136839›Full record

ReviewCell biochemistry and biophysics2024

Circular RNA as a Biomarker for Diagnosis, Prognosis and Therapeutic Target in Acute and Chronic Lymphoid Leukemia.

Mohammad Abohassan, Abdulrahman Qais Khaleel, Harikumar Pallathadka, Ashwani Kumar, Omer Qutaiba B Allela, Ahmed Hjazi, Atreyi Pramanik, Yasser Fakri Mustafa, Hamza Fadhel Hamzah, Bahira Abdulrazzaq Mohammed

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cell biochemistry and biophysics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohammad AbohassanDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Abdulrahman Qais KhaleelDepartment of Medical Instruments Engineering, Al-Maarif University College, Al Anbar, 31001, Iraq. Abdulrahman.qais@uoa.edu.iq.
Harikumar PallathadkaManipur International University, Imphal, Manipur, India.
Ashwani KumarDepartment of Life Sciences, School of Sciences, Jain (Deemed-to-be) University, Bengaluru, Karnataka, 560069, India.
Omer Qutaiba B AllelaCollege of Pharmacy, Al-Noor University, Mosul, Iraq.
Ahmed HjaziDepartment of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.
Atreyi PramanikSchool of Applied and Life Sciences, Ivison of Research and Innovation Uttaranchal University, Dehradun, India.
Yasser Fakri MustafaDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq.
Hamza Fadhel HamzahDepartment of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq.
Bahira Abdulrazzaq MohammedDepartment of of technical engineering, Al-Hadi University College, Baghdad, 10011, Iraq.

Funding

Deanship of Scientific Research, King Khalid University R.G.P.2/315/44
6 · The paper itself

Abstract

Circular RNAs (circRNAs) are single-stranded RNAs that have received much attention in recent years. CircRNAs lack a 5' head and a 3' poly-A tail. The structure of this type of RNAs make them resistant to digestion by exonucleases. CircRNAs are expressed in different cells and have various functions. The function of circRNAs is done by sponging miRNAs, changing gene expression, and protein production. The expression of circRNAs changes in different types of cancers, which causes changes in cell growth, proliferation, differentiation, and apoptosis. Changes in the expression of circRNAs can cause the invasion and progression of tumors. Studies have shown that changes in the expression of circRNAs can be seen in acute lymphoid leukemia (ALL) and chronic lymphoid leukemia (CLL). The conducted studies aim to identify circRNAs whose expression has changed in these leukemias and their more precise function so that these circRNAs can be identified as biomarkers, prediction of patient prognosis, and treatment targets for ALL and CLL patients. In this study, we review the studies conducted on the role and function of circRNAs in ALL and CLL patients. The results of the studies show that there is a possibility of using circRNAs as biomarkers in the identification and treatment of patients in the future.

Indexed as

Biomarkers, TumorLeukemia, Lymphocytic, Chronic, B-CellPrecursor Cell Lymphoblastic Leukemia-LymphomaRNA, CircularHumansMicroRNAsPrognosisRNABiomarkers, TumorMicroRNAsRNARNA, CircularAcute lymphoid leukemiaChronic lymphoid leukemiaCircRNADiagnosismiRNATreatment

Identifiers

PMID39136839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.